超越利福平:利福喷丁与利福布汀作为结核性脑膜炎替代治疗的评价
本研究在小鼠颅内接种结核分枝杆菌模型中,以人体等效剂量比较利福平、利福喷丁或利福布汀方案的杀菌活性、组织浓度、脑炎症与神经元损伤。结果显示含利福喷丁或利福布汀方案脑内杀菌活性相似或优于标准利福平方案,并减轻神经炎症与脑损伤,支持开展临床试验评估。
要点
- 利福喷丁或利福布汀方案脑内杀菌活性相似或优于标准利福平方案。
- 两方案均减轻脑神经炎症与脑损伤,具神经保护作用。
- 结果支持在结核性脑膜炎临床试验中评估这两种利福霉素。
核心结论
- 利福喷丁和利福布汀在结核性脑膜炎小鼠模型中显示治疗活性与神经保护效应,支持临床转化评估。
研究设计与样本
- 小鼠颅内接种结核分枝杆菌后,以人体等效剂量给予含利福平、利福喷丁或利福布汀的方案治疗。
- 评估三项方案的杀菌活性、利福霉素组织浓度、脑炎症(脑磁共振成像、组织免疫荧光、细胞因子)及神经元损伤。
主要发现
- 含利福喷丁和利福布汀方案在脑内均显示杀菌活性,相似或优于标准含利福平方案。
- 两方案均减少神经炎症和脑损伤。
临床怎么用
- 提示利福喷丁和利福布汀可作为结核性脑膜炎的候选替代利福霉素,但需临床试验验证后方可用于临床决策。
局限性
- 证据来自小鼠模型,尚需人体临床试验确认疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis, carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary tuberculosis, with rifapentine now forming the basis of a World Health Organization-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well tolerated, however, both drugs still need dedicated evaluation in TB meningitis. METHODS: Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine, or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the 3 regimens, rifamycin tissue concentrations, brain inflammation (brain magnetic resonance imaging, tissue immunofluorescence, cytokines), and neuronal injury. RESULTS: Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury. CONCLUSIONS: Alternate rifamycins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.
引用
- Chen X, Ruiz-Gonzalez CE, Masias-Leon Y, et al. Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for Tuberculous Meningitis. J Infect Dis. 2026. PMID: 41666165. doi:10.1093/infdis/jiag087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。